Precise Diagnosis, Treatment and Prognostic Evaluation of Complicated Adrenal Tumor Diseases
The adrenal gland is an important organ that produces life hormones. There are many types of adrenal tumors, which tend to occur in young adults and affect the whole body. It has the dual threat: hormone secretion and tumor metastasis. At present, there are four major dilemmas in the clinical diagnosis and treatment of adrenal tumors: 1) Pulse secretion of the hormones, which are affected by many factors; and the diagnostic value of single hormone is limited; 2) Traditional imaging cannot accurately reflect the characteristics of hormone secretion. The prognosis cannot be accurately predicted; 3) The molecular characteristics of tumor cells and the microenvironment are unclear, making it difficult to implement early diagnosis and precise treatment; 4) Traditional pathology cannot determine the nature and long-term prognosis of the tumor, which makes the treatment delay, and the disease prognosis is extremely poor. It threatens the lives of patients.
Starting from solving the above-mentioned key problems in the early stage, the research team has systematically established new clinical diagnostic technologies, hormone dynamic tests to accurately assess hormone secretion and segmented blood collection hormone determination technologies to accurately locate adrenal tumors; A series of important research results have been published in Science, Lancet Diabetes & Endocrinology, Cell Research, etc To sum up, the goal of this research is improving the early diagnosis rate of complicated adrenal tumors especially in malignant tumors, developing the optimal treatment plan, avoiding unnecessary surgical treatment, improving the quality of life of patients, reducing mortality. This project will further integrate the adrenal cortex and medulla hormone mass spectrometry detection and the molecular markers of adrenal tumors through phenotypic, functional imaging, and molecular pathological evaluations, and built a sensitive drug screening platform that integrates visual drug response and molecular characteristics, thereby achieving precise diagnosis and treatment of complicated adrenal tumors.
研究概览
研究类型
注册 (预期的)
联系人和位置
学习联系方式
- 姓名:Yiran Jiang, MD
- 电话号码:8621-64370045
- 邮箱:rainy0409@hotmail.com
研究联系人备份
- 姓名:Luming Wu, PhD
- 电话号码:8621-64370045
- 邮箱:wulum@126.com
学习地点
-
-
Shanghai
-
Shanghai、Shanghai、中国、200025
- 招聘中
- Ruijin Hospital
-
接触:
- Yiran Jiang
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Inclusion Criteria:
- Age ≥ 18 years old and ≤ 75 years
- Diagnosis of Patients with primary aldosteronism, pheochromocytoma, and cortical cancer
- Gender: males and females
- Provide written informed consent
- Satisfactory compliance
Exclusion Criteria:
- Patients with renal insufficiency (Cr>2 times the upper limit of normal).
- Patients with a history of liver cirrhosis.
- Patients who are currently using corticosteroids.
- Patients with cardiac insufficiency (NYHA cardiac function classification grade 3 and above or EF<50%).
- Patients with stroke and acute myocardial infarction in the past 6 months.
- Patients during pregnancy and lactation
描述
Inclusion Criteria:
- Age ≥ 18 years old and ≤ 75 years
- Diagnosis of Patients with primary aldosteronism, pheochromocytoma, and cortical cancer
- Gender: males and females
- Provide written informed consent
- Satisfactory compliance
Exclusion Criteria:
- Patients with renal insufficiency (Cr>2 times the upper limit of normal).
- Patients with a history of liver cirrhosis.
- Patients who are currently using corticosteroids.
- Patients with cardiac insufficiency (NYHA cardiac function classification grade 3 and above or EF<50%).
- Patients with stroke and acute myocardial infarction in the past 6 months.
- Patients during pregnancy and lactation
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
primary aldosteronism
|
pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results
|
pheochromocytoma
|
pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results
|
adrenocortical carcinoma
|
pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
tumor biochemical marker treatment response
大体时间:20 years
|
|
20 years
|
Tumor volume assessment: According to RECIST (version 1.1).
大体时间:20 years
|
|
20 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
surgery or drug的临床试验
-
St. Joseph's Healthcare HamiltonHamilton Academic Health Sciences Organization完全的